ReviewPediatric nephrology (Berlin, Germany)2016
Growth hormone therapy in children with CKD after more than two decades of practice.
Review in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.Nature reviews. Nephrology · 2019Guideline
- Linear growth in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2026Article
- Chronic Kidney Disease Interplay with Comorbidities and Carbohydrate Metabolism: A Review.Life (Basel, Switzerland) · 2023Review
- Longitudinal Relationship Between Anemia and Statural Growth Impairment in Children and Adolescents With Nonglomerular CKD: Findings From the Chronic Kidney Disease in Children (CKiD) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Article
- Growth hormone therapy in pediatric kidney transplantation-the long-term clinical benefits beyond improvement of growth after withdrawal of pre-transplant therapy.Pediatric nephrology (Berlin, Germany) · 2022Article
- Effectiveness of growth hormone on growth and final height in paediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2022Article
- Renal effects of growth hormone in health and in kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Article
- Decreased insulin-like growth factor-1 (IGF-1) concentration correlates with reduced left-ventricle ejection fraction (LVEF) in hemodialysis patients.International urology and nephrology · 2020Article
- Summary of Expert Opinion on the Management of Children With Chronic Kidney Disease and Growth Failure With Human Growth Hormone.Frontiers in endocrinology · 2020Article
- Treatment of Growth Retardation in a Child with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2019Article
- Short stature in advanced pediatric CKD is associated with faster time to reduced kidney function after transplant.Pediatric nephrology (Berlin, Germany) · 2019Article
- Growth and Nutrition in Pediatric Chronic Kidney Disease.Frontiers in pediatrics · 2018Review
- Pubertal development in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2017Review
- Approach to growth hormone therapy in children with chronic kidney disease varies across North America: the Midwest Pediatric Nephrology Consortium report.BMC nephrology · 2017Article
- Growth hormone therapy for a patient with idiopathic Fanconi syndrome and growth hormone deficiency.CEN case reports · 2017Article
- Chronic kidney disease in children.Clinical kidney journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on the evidence for the efficacy and safety of recombinant human growth hormone (rhGH) therapy in children with all stages of chronic kidney disease (CKD) and at all ages. It describes the improving height prognosis for our patients both with and without rhGH; explains the underlying hormonal abnormalities that provide the rationale for rhGH use in CKD and the endocrine changes that accompany treatment; and views on who warrants treatment, with what dose, and how long for.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.